Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections

Antiviral Research

Volumn 30, Issue 2-3, 1996, Pages 125-132

  Neyts, J ^a   Meerbach, A ^a   McKenna, P ^a   De Clercq, E ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

EICAR; Flaviviruses; Hepatitis C virus; Mycophenolic acid; Ribavirin; Yellow fever virus

Indexed keywords

1 (4,5 DIHYDROXY 3 HYDROXYMETHYL 2 CYCLOPENTEN 1 YL)CYTOSINE; 3 DEAZANEPLANOCIN A; 5 ETHYNYL 1BETA DEXTRO RIBOFURANOSYLIMIDAZOLE 4 CARBOXAMIDE; 5 FORMYLDEOXYURIDINE; ANTIVIRUS AGENT; AZAURIDINE; CARBODINE; DEXTRAN SULFATE; FLOXURIDINE; IDOXURIDINE; METHOTREXATE; MYCOPHENOLIC ACID; NEPLANOCIN A; RIBAVIRIN; S ADENOSYLHOMOCYSTEINE HYDROLASE INHIBITOR; SELENAZOFURIN; THYMIDYLATE SYNTHASE INHIBITOR; TIAZOFURIN; TRIFLURIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XYLOTUBERCIDIN; YELLOW FEVER VACCINE;

ANIMAL CELL; ARTICLE; BUNYAVIRUS; CONTROLLED STUDY; CYTOTOXICITY; DRUG TARGETING; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS; NONHUMAN; PRIORITY JOURNAL; VERO CELL; VIRUS INFECTION; VIRUS REPLICATION; YELLOW FEVER FLAVIVIRUS;

ANIMALIA; FLAVIVIRUS; HEPATITIS C VIRUS; HERPES; ORTHOBUNYAVIRUS; SIMPLEXVIRUS; YELLOW FEVER VIRUS;

EID: 0029888393     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/0166-3542(96)89697-5     Document Type: Article

References (27)

1. Arroyo, J.I., Apperson, S.A., Cropp, C.B., Marafino Jr., B.J., Monath, T.P., Tesh, R.B., Shope, R.E. and Garcia-Blanco, M.A. (1988) Effect of human gamma interferon on yellow fever virus infection. Am. J. Trop. Med. Hyg. 38, 647-650.
2. Balzarini, J., Karlsson, A., Wang, L., Bohman, C., Horská, K., Votruba, I., Fridland, A., Van Aerschot, A., Herdewijn, P. and De Clercq, E. (1993) EICAR (5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide): a novel potent inhibitor of IMP dehydrogenase activity and guanylate biosynthesis. J. Biol. Chem. 268, 24 591-24 599.
3. De Clercq, E. (1987) S-adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents. Biochem. Pharmacol. 36, 2567-2575.
4. De Clercq, E., Cools, M., Balzarini, J., Snoeck, R., Andrei, G., Hosoya, M., Shigeta, S., Ueda, T., Minakawa, N. and Matsuda, A. (1991a) Antiviral activities of 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide and related compounds. Antimicrob. Agents Chemother. 35, 679-684.
5. De Clercq, E., Murase, J. and Marquez, V.E. (1991b) Broad-spectrum antiviral and cytocidal activity of cyclopentenylcytosine, a carbocyclic nucleoside targeted at CTP synthetase. Biochem. Pharmacol. 41, 1821-1829.
6. Descamps, J. and De Clercq, E. (1978) Broad-spectrum antiviral activity of pyrazofurin (pyrazomycin). In: Siegenthaler, W. and Lüthy, R.,(Eds.), Current Chemotherapy, pp 354-357. American Society for Microbiology, Washington DC.
7. Di-Bisaglie, A.M., Shindo, M., Fong, T.L., Fried, M.W., Swain, M.G., Bergasa, N.V., Axiotis, C.A., Waggoner, J.G., Park, Y. and Hoofnagle, J.H. (1992) A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 16, 649-654.
8. Eugui, E.M., Mirkovich, A. and Allison, A.C. (1991) Lymphocyte-selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in rodents. Transplant. Proc. 23, Suppl. 2, 15-18.
9. Glazer, R.I., Knode, M.C., Linn, M.I. and Marquez, V.E. (1985) Cyclopentenyl cytidine analogue. An inhibitor of cytidine triphosphate synthesis in human colon carcinoma cells. Biochem. Pharmacol. 34, 2535-2539.
10. Goswami, B.B., Borek, E., Sharma, O.K., Fujitaki, J. and Smith, R.A. (1979) The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem. Biophys. Res. Commun. 89, 830-836.
11. Muggins, J.W., Robins, R.K. and Canonico, P.G. (1984) Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses. Antimicrob. Agents Chemother. 26, 476-480.
12. Ichimura, H. and Levy, J.A. (1995) Polymerase substrate depletion is a novel strategy for inhibiting the replication of the human immunodeficiency virus. Virology 211, 554-560.
13. Janeway, C.M. and Cha, S. (1977) Effects of 6-azauridine on nucleotides, orotic acid, and oritidine in L5178Y mouse lymphoma cells in vitro. Cancer Res. 37, 4382-4388.
14. Jones, A.S., Verhelst, G. and Walker, R.T. (1979) The synthesis of the potent antiherpes virus agent (E)-5-(2-bromovinyl)-2′-deoxyuridine and related compounds. Tetrahedron Lett. 45, 4415-4418.
15. Kang, G.J., Cooney, D.A., Mayer, J.D., Kelley, J.A., Kim, H.Y., Marquez, V.E. and Johns, D.G. (1989) Cyclopentenylcytosine triphosphate. Formation and inhibition of CTP synthetase. J. Biol. Chem. 264, 713-718.
16. Kirsi, J.J., North, J.A., Mc Kernan, P.A., Murray, B.K., Canonico, P.G., Huggins, J.W., Srivastava, P.C. and Robins, R.K. (1983) Broad spectrum antiviral activity of 2-β-D-ribofuranosylselen zole-4-carboxamide, a new antiviral agents. Antimicrob. Agents Chemother. 24, 353-361.
17. Marquez, V.E., Linn, M.-I., Treanor, S.P., Plowman, J., Priest, M.A., Markovac, A., Khan, M.S., Kaskar, B. and Driscoll, J.S. (1988) Cyclopentenylcytosine. A carbocyclic nucleoside with antitumor and antiviral properties. J. Med. Chem. 31, 1687-1694.
18. Monath, T.P. (1987) Yellow fever: a medically neglected disease. Report on a seminar. Rev. Infect. Dis. 9, 165-175.
19. Monath, T.P. (1990) Flaviviruses. In: Fields, B.N., Knipe, D.M., Chanock, R.M., Hirsch, M.S., Melnick, J.L., Monath, T.P. and Roizman B.,(Eds.), Virology (2nd edition), pp.763-814. Raven Press, New York.
20. Neyts, J., Snoeck, R., Schols, D., Balzarini, J., Esko, J.D., Van Schepdael, A. and De Clercq, E. (1992) Sulfated polymers inhibit the interaction of human cytomegalovirus with cell surface heparan sulfate. Virology 189, 48-58.
21. Schols, D., De Clercq, E., Balzarini, J., Baba, M., Witvrouw, M., Hosoya, M., Andrei, G., Snoeck, R., Neyts, J., Pauwels, R., Nagy, M., Györgyi-Edelényi, J., Machovich, R., Horváth, I., Löw, M. and Görög, S. (1990) Sulfated polymers are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, respiratory syncytial virus, and toga-, arena-and retroviruses. Antiviral Chem. Chemother. 1, 223-240.
22. Taylor, D.O., Ensley, R.D., Olsen, S.L., Dunn, D. and Renlund, D.G. (1994) Mycophenolate mofetil (RS-61443): preclinical, clinical and three-year experience in heart transplantation. J. Heart Lung Transpl. 13, 571-582.
23. Theiler, M. and Smith, H.H. (1937) The use of yellow virus modified by in vitro cultivations for human immunization. J. Exp. Med. 65, 787-800.
24. Tseng, C.K.H., Marquez, V.E., Fuller, R.W., Goldstein, B.M., Haines, D.R., McPherson, H., Parsons, J.L., Shannon, W.M., Arnett, G., Hollingshead, M. and Driscoll, J.S. (1989) Synthesis of 3-deazaneplanocin A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities. J. Med. Chem. 32, 1442-1446.
25. WHO Notes and News (1993) Resurgence of yellow fever. World Health Forum 14, 91-92.
26. Wray, S.K., Gilbert, B.E. and Knight, V. (1985) Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antiviral Res. 5, 39-48.
27. Wu-Dunn, D. and Spear, P.G. (1989) Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J. Virol. 63, 52-58.